7-117535318-A-G
Position:
Variant summary
Our verdict is Benign. Variant got -7 ACMG points: 2P and 9B. PM1BP4_StrongBP6BS2
The NM_000492.4(CFTR):āc.650A>Gā(p.Glu217Gly) variant causes a missense change involving the alteration of a conserved nucleotide. The variant allele was found at a frequency of 0.00206 in 1,614,056 control chromosomes in the GnomAD database, including 67 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Genomes: š 0.0034 ( 9 hom., cov: 32)
Exomes š: 0.0019 ( 58 hom. )
Consequence
CFTR
NM_000492.4 missense
NM_000492.4 missense
Scores
1
9
8
Clinical Significance
Conservation
PhyloP100: 8.84
Genes affected
CFTR (HGNC:1884): (CF transmembrane conductance regulator) This gene encodes a member of the ATP-binding cassette (ABC) transporter superfamily. The encoded protein functions as a chloride channel, making it unique among members of this protein family, and controls ion and water secretion and absorption in epithelial tissues. Channel activation is mediated by cycles of regulatory domain phosphorylation, ATP-binding by the nucleotide-binding domains, and ATP hydrolysis. Mutations in this gene cause cystic fibrosis, the most common lethal genetic disorder in populations of Northern European descent. The most frequently occurring mutation in cystic fibrosis, DeltaF508, results in impaired folding and trafficking of the encoded protein. Multiple pseudogenes have been identified in the human genome. [provided by RefSeq, Aug 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -7 ACMG points.
PM1
In a domain ABC transmembrane type-1 1 (size 284) in uniprot entity CFTR_HUMAN there are 65 pathogenic changes around while only 10 benign (87%) in NM_000492.4
BP4
Computational evidence support a benign effect (MetaRNN=0.008159667).
BP6
Variant 7-117535318-A-G is Benign according to our data. Variant chr7-117535318-A-G is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 7238.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=2, Uncertain_significance=11, Benign=2}. Variant chr7-117535318-A-G is described in Lovd as [Likely_benign].
BS2
High Homozygotes in GnomAd4 at 9 AR gene
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CFTR | NM_000492.4 | c.650A>G | p.Glu217Gly | missense_variant | 6/27 | ENST00000003084.11 | NP_000483.3 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CFTR | ENST00000003084.11 | c.650A>G | p.Glu217Gly | missense_variant | 6/27 | 1 | NM_000492.4 | ENSP00000003084.6 |
Frequencies
GnomAD3 genomes AF: 0.00339 AC: 516AN: 152084Hom.: 9 Cov.: 32
GnomAD3 genomes
AF:
AC:
516
AN:
152084
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00444 AC: 1117AN: 251436Hom.: 27 AF XY: 0.00406 AC XY: 552AN XY: 135888
GnomAD3 exomes
AF:
AC:
1117
AN:
251436
Hom.:
AF XY:
AC XY:
552
AN XY:
135888
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00193 AC: 2815AN: 1461854Hom.: 58 Cov.: 32 AF XY: 0.00183 AC XY: 1333AN XY: 727224
GnomAD4 exome
AF:
AC:
2815
AN:
1461854
Hom.:
Cov.:
32
AF XY:
AC XY:
1333
AN XY:
727224
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.00338 AC: 515AN: 152202Hom.: 9 Cov.: 32 AF XY: 0.00477 AC XY: 355AN XY: 74414
GnomAD4 genome
AF:
AC:
515
AN:
152202
Hom.:
Cov.:
32
AF XY:
AC XY:
355
AN XY:
74414
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
4
ExAC
AF:
AC:
476
Asia WGS
AF:
AC:
53
AN:
3478
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Pathogenic:1Uncertain:13Benign:6
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not provided Uncertain:6Benign:3
Uncertain significance, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Nov 27, 2023 | The CFTR c.650A>G; p.Glu217Gly variant (rs121909046) is reported in the literature in patients affected with congenital bilateral absence of vas deferens (Cheng 2022, Fang 2022, Li 2012, Luo 2021), bronchiectasis (Guan 2018, Lee 2003), chronic pancreatitis (Masson 2013, Steiner 2011, Xiao 2017), or cystic fibrosis (Petrova 2020, Shen 2022). This variant is also reported in ClinVar database (Variation ID: 7238) and is found in the Finnish European population with an allele frequency of 3.5% (875/25118 alleles, including 25 homozygotes) in the Genome Aggregation Database (v2.1.1). Computational analyses are uncertain whether this variant is neutral or deleterious (REVEL: 0.546). However, functional analyses of the variant protein show reduced function in vitro (Hammerle 2001, Lee 2003). Due to conflicting information, the clinical significance of this variant is uncertain at this time. References: Cheng H et al. Genetic analysis and intracytoplasmic sperm injection outcomes of Chinese patients with congenital bilateral absence of vas deferens. J Assist Reprod Genet. 2022 Mar;39(3):719-728. PMID: 35119551. Fang J et al. Congenital absence of the vas deferens with hypospadias or without hypospadias: Phenotypic findings and genetic considerations. Front Genet. 2022 Nov 9;13:1035468. PMID: 36437957. Guan et al. Next-generation sequencing for identifying genetic mutations in adults with bronchiectasis. J Thorac Dis. 2018 May;10(5):2618-2630. PMID: 29997923. Hammerle MM et al. Disease-associated mutations in the extracytoplasmic loops of cystic fibrosis transmembrane conductance regulator do not impede biosynthetic processing but impair chloride channel stability. J Biol Chem. 2001 May 4;276(18):14848-54. PMID: 11278813. Lee JH et al. A haplotype-based molecular analysis of CFTR mutations associated with respiratory and pancreatic diseases. Hum Mol Genet. 2003 Sep 15;12(18):2321-32. PMID: 12952861. Li H et al. Mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) in Chinese patients with congenital bilateral absence of vas deferens. J Cyst Fibros. 2012 11(4):316-23. PMID: 22483971. Luo et al. Mutation analysis of the cystic fibrosis transmembrane conductance regulator gene in Chinese congenital absence of vas deferens patients. Gene. 2021 Jan 10;765:145045. PMID: 32777524. Masson E et al. A conservative assessment of the major genetic causes of idiopathic chronic pancreatitis: data from a comprehensive analysis of PRSS1, SPINK1, CTRC and CFTR genes in 253 young French patients. PLoS One. 2013 8(8):e73522. PMID: 23951356. Petrova NV et al. Analysis of CFTR Mutation Spectrum in Ethnic Russian Cystic Fibrosis Patients. Genes (Basel). 2020 May 15;11(5):554. PMID: 32429104. Shen Y et al. Genetic spectrum of Chinese children with cystic fibrosis: comprehensive data analysis from the main referral centre in China. J Med Genet. 2022 Jul 20;60(3):310ā5. PMID: 35858753. Steiner B et al . Common CFTR haplotypes and susceptibility to chronic pancreatitis and congenital bilateral absence of the vas deferens. Hum Mutat. 2011 32(8):912-20. PMID: 21520337. Xiao et al. Targeted Gene Next-Generation Sequencing in Chinese Children with Chronic Pancreatitis and Acute Recurrent Pancreatitis. J Pediatr. 2017 Dec;191:158-163.e3. PMID: 29173301. - |
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Nov 01, 2024 | CFTR: BS2 - |
Uncertain significance, criteria provided, single submitter | clinical testing | GeneDx | Apr 04, 2023 | Observed with CF-causing variants on the opposite allele (in trans) in asymptomatic individuals (Claustres et al., 2017); Observed in the homozygous state in healthy adult individuals tested at GeneDx and in large population cohorts (gnomAD); In silico analysis supports that this missense variant does not alter protein structure/function; This variant is associated with the following publications: (PMID: 25087612, 23951356, 29058463, 34426522, 17516627, 21520337, 34405919, 29307731, 15463840, 11589722, 16126774, 11938439, 22664493, 26089335, 34996830, 16596947, 20558957, 17539902, 10922396, 22483971, 32777524, 32429104, 29173301, 24586523, 12952861, 27706244, 26436105, 20879059, 29997923, 18304229, 31916691, 11278813, 28603918, 31882543) - |
Uncertain significance, criteria provided, single submitter | clinical testing | Clinical Genetics Laboratory, Skane University Hospital Lund | May 27, 2022 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Jan 13, 2023 | BS1, BS2, PM3_strong, PS3 - |
Uncertain significance, criteria provided, single submitter | clinical testing | Eurofins Ntd Llc (ga) | Jul 10, 2018 | - - |
Likely benign, no assertion criteria provided | clinical testing | Diagnostic Laboratory, Department of Genetics, University Medical Center Groningen | - | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Quest Diagnostics Nichols Institute San Juan Capistrano | Feb 04, 2021 | - - |
Likely benign, no assertion criteria provided | clinical testing | Clinical Genetics DNA and cytogenetics Diagnostics Lab, Erasmus MC, Erasmus Medical Center | - | - - |
Cystic fibrosis Pathogenic:1Uncertain:5Benign:2
Uncertain significance, criteria provided, single submitter | curation | Institute of Human Genetics, University of Leipzig Medical Center | Sep 05, 2022 | This variant was identified in 2 unrelated patients with a clinically confirmed diagnosis of cystic fibrosis. The variant was classified in the context of a project re-classifying variants in the German Cystic Fibrosis Registry (Muko.e.V.). Link: https://www.muko.info/angebote/qualitaetsmanagement/register/cf-einrichtungen/mukoweb. Criteria applied: PS3_MOD, PM3, BS2, BP2 - |
Pathogenic, no assertion criteria provided | literature only | OMIM | Sep 15, 2003 | - - |
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Feb 01, 2024 | - - |
Uncertain significance, no assertion criteria provided | clinical testing | Natera, Inc. | Jun 13, 2017 | - - |
Uncertain significance, criteria provided, single submitter | clinical testing | Genome-Nilou Lab | Jun 10, 2021 | - - |
Uncertain significance, criteria provided, single submitter | reference population | Soonchunhyang University Bucheon Hospital, Soonchunhyang University Medical Center | Mar 18, 2016 | - - |
Benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 02, 2018 | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mendelics | May 28, 2019 | - - |
CFTR-related disorder Uncertain:1Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Illumina Laboratory Services, Illumina | Apr 27, 2017 | This variant was observed as part of a predisposition screen in an ostensibly healthy population. A literature search was performed for the gene, cDNA change, and amino acid change (where applicable). Publications were found based on this search. The evidence from the literature, in combination with allele frequency data from public databases where available, was sufficient to determine this variant is unlikely to cause disease. Therefore, this variant is classified as likely benign. - |
Uncertain significance, no assertion criteria provided | clinical testing | Genome Diagnostics Laboratory, The Hospital for Sick Children | Apr 29, 2021 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 05, 2024 | Variant summary: CFTR c.650A>G (p.Glu217Gly) results in a non-conservative amino acid change located in the ABC transporter type 1, transmembrane domain (IPR011527) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 0.0047 in 259928 control chromosomes, including 29 homozygotes (gnomAD and publications); particularly at a frequency of 0.0095 within the East Asian subpopulation in the gnomAD database. This frequency is approximately equal to the estimated maximal expected allele frequency for a pathogenic variant in CFTR causing CFTR-related diseases phenotype (0.0095 vs 0.013), suggesting that the variant may be a benign polymorphism. c.650A>G has been reported in the literature in individuals affected with CFTR-Related Diseases such as Cystic Fibrosis (CF), chronic pancreatitis and CBAVD (example: Audrezet_2002, Guan_2018, Petrova_2020, Luo_2021), but also in many controls (example: Kars_2021). These reports do not provide unequivocal conclusions about association of the variant with CFTR-Related Diseases. Munck et al (2019) report a patient with inconclusive CF diagnosis harboring a second allele of F508del, with sweat chloride levels < 30 mmol/L. Nevertheless, Petroval et al (2020) report another patient with F508del in trans who had a diagnosis of CF, with sweat chloride levels of 63 mmol/L. CFTR-France database reports this variant in two asymptomatic compound heterozygotes with a CF-causing variant in trans. Functional studies report significantly decreased chloride channel activity associated with the variant when transfected into CHO-K1 and BHK cells (Hammerl_2001, Lee_2003, Chang_2018, Bihler_2024). The following publications have been ascertained in the context of this evaluation (PMID: 15463840, 11938439, 16596947, 38388235, 29307731, 17539902, 29997923, 11278813, 34426522, 20879059, 26089335, 31882543, 12952861, 22483971, 32777524, 22664493, 16126774, 31916691, 32429104, 31245908, 18304229, 21520337, 26436105, 11589722, 27706244, 31423445, 17516627, 24586523). ClinVar contains an entry for this variant (Variation ID: 7238). Based on the evidence outlined above, the variant was classified as VUS-possibly benign. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Uncertain
CADD
Uncertain
DANN
Uncertain
DEOGEN2
Uncertain
D;.;.;D;.
Eigen
Benign
Eigen_PC
Uncertain
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D;D;D;D;D
MetaRNN
Benign
T;T;T;T;T
MetaSVM
Uncertain
D
MutationAssessor
Benign
L;.;.;.;L
PrimateAI
Benign
T
PROVEAN
Benign
N;.;.;N;.
REVEL
Uncertain
Sift
Uncertain
D;.;.;D;.
Sift4G
Uncertain
D;.;.;D;.
Polyphen
B;.;.;.;.
Vest4
MVP
MPC
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at